139 related articles for article (PubMed ID: 14526586)
1. [New protease inhibitor against HIV. Viral load decreases--without lipid increase].
MMW Fortschr Med; 2003 Aug; 145(33-34):61. PubMed ID: 14526586
[No Abstract] [Full Text] [Related]
2. [Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():90. PubMed ID: 15373065
[No Abstract] [Full Text] [Related]
3. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
4. [Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():44. PubMed ID: 15373047
[No Abstract] [Full Text] [Related]
5. [New data on atazanavir/r]].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
[No Abstract] [Full Text] [Related]
6. Boosted Reyataz: 48-week results.
Huff B
GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
[No Abstract] [Full Text] [Related]
7. [Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
MMW Fortschr Med; 2003 Dec; 145(50):61. PubMed ID: 14963981
[No Abstract] [Full Text] [Related]
8. A new protease inhibitor from Bristol-Myers Squibb.
TreatmentUpdate; 2001; 12(12):5. PubMed ID: 11570092
[No Abstract] [Full Text] [Related]
9. [HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
MMW Fortschr Med; 2014 Jun; 156 Suppl 1():52. PubMed ID: 25026859
[No Abstract] [Full Text] [Related]
10. HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Bierman WF; van Agtmael MA; Nijhuis M; Danner SA; Boucher CA
AIDS; 2009 Jan; 23(3):279-91. PubMed ID: 19114854
[TBL] [Abstract][Full Text] [Related]
11. 96-week data from CASTLE study presented.
Proj Inf Perspect; 2008 Dec; (47):3-4. PubMed ID: 19230058
[No Abstract] [Full Text] [Related]
12. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
13. [New treatment options for HIV-infected patients].
Wehr A
Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
[No Abstract] [Full Text] [Related]
14. Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Prescrire Int; 2009 Jun; 18(101):104. PubMed ID: 19637415
[TBL] [Abstract][Full Text] [Related]
15. Anti-HIV agents. Kaletra + atazanavir.
TreatmentUpdate; 2005; 17(5):5. PubMed ID: 17219657
[No Abstract] [Full Text] [Related]
16. Reyataz monotherapy study stopped.
Proj Inf Perspect; 2007 Oct; (44):23-4. PubMed ID: 18046835
[No Abstract] [Full Text] [Related]
17. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
[No Abstract] [Full Text] [Related]
18. Anti-HIV agents. Atazanavir and saquinavir.
TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
[No Abstract] [Full Text] [Related]
19. [Maintaining independence. New protease inhibitor receives drug approval recommendation].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():84-5. PubMed ID: 15373062
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
